| Clobazam |
Film | V (Paddle over Disk), with 56 mm, 40 mesh stainless steel disk. | 75 | 0.1 N HCl | 900 | 2, 5, 10, 15, 20 and 30 | 2021-04-22 |
| Esomeprazole Magnesium |
Tablet (Orally Disintegrating, Delayed Release) | II (Paddle) | Acid stage: 100; Buffer stage: 75 | Acid stage: 0.1 N HCl; Buffer stage: Phosphate Buffer, pH 6.8 | Acid stage: 300; Buffer stage: 1000 | Acid stage: 120; Buffer stage: 5, 10, 20, 30 and 45 | 2021-04-22 |
| Carbidopa/Levodopa |
Tablet | | | Refer to FDA's Dissolution Guidance, 2018 | | | 2021-04-22 |
| Mexiletine HCl |
Capsule | | | Refer to FDA's Dissolution Guidance, 2018 | | | 2021-04-22 |
| Erythromycin Ethylsuccinate |
Tablet | | | Refer to USP | | | 2021-04-22 |
| Levorphanol Tartrate |
Tablet | | | Refer to FDA's Dissolution Guidance, 2018 | | | 2021-04-22 |
| Isotretinoin |
Capsule | | | Refer to USP | | | 2021-04-22 |
| Prucalopride Succinate |
Tablet | | | Refer to FDA's Dissolution Guidance, 2018 | | | 2021-04-22 |
| Asenapine |
Transdermal | VI (Cylinder) | 50 | pH 5.1 Acetate Buffer at 32°C | 900 | 1, 2, 3, 4, 6, 8, 10 and 12 hours | 2021-04-22 |
| Octreotide Acetate |
Capsule (Delayed Release) | II (Paddle with sinker) | 50 | Acid stage: 0.1N HCl ; Buffer stage: pH 6.8 buffer | Acid stage: 900; Buffer stage: 900 | Acid stage: 120; Buffer stage: 10, 20, 30 45 and 60 | 2021-04-22 |
| Rifamycin Sodium |
Tablet (Delayed Release) | II (Paddle) | 100 | Acid stage: HCl 0.1 N with 0.5% w/v Macrogol Cetostearyl Ether; Buffer stage: pH 7.2 Sodium Phosphate buffer | | Acid Stage: 2 hours; Buffer Stage: 1, 2, 3 and 4 hours | 2021-04-22 |
| Prochlorperazine Maleate |
Tablet | II (Paddle) | 75 | 0.1 N HCl | 500 | 10, 20, 30, 45, 60, 75, and 90 | 2021-04-22 |
| Ceritinib |
Tablet | I (Basket) | 75 | 0.01 N HCl (degassed) | 900 | 5, 10, 15, 20 and 30 | 2021-04-22 |
| Quinidine Gluconate |
Tablet (Extended Release) | | | Refer to USP | | | 2021-04-22 |
| Lefamulin Acetate |
Tablet | II (Paddle) | 50 | 0.1 N HCl | 1000 | 10, 20, 30, 45, 60, 75, and 90 | 2021-04-22 |
| Propranolol HCl |
Tablet | | | Refer to FDA's Dissolution Guidance, 2018 | | | 2021-04-22 |
| Pretomanid |
Tablet | II (Paddle) | 75 | 0.1 N HCl with 0.5% hexadecyltrimethylammonium (HDTMA) | 1000 | 5, 10, 15, 20, 30 and 45 | 2021-04-22 |
| Fostemsavir Tromethamine |
Tablet (Extended Release | I (Basket) | 100 | 0.05 M Phosphate Buffer, pH 6.8 buffer, pH 6.8 | 900 | 1, 2, 3, 5, 7, 10, 12, 16, 20 and 24 hours | 2021-04-22 |
| Elagolix Sodium |
Tablet | II (Paddle) | 50 | 0.05 M Sodium Phosphate, pH 6.8 | 900 | 5, 10, 15, 20, 30 and 45 | 2021-04-22 |
| Tafamidis |
Capsule | II (Paddle) with sinker | 75 | Tier 1 Medium: 0.05M Sodium Phosphate Buffer, pH 6.8 with 1.0% Tween 80; Tier II Medium: 0.05M Sodium Phosphate Buffer, pH 6.8 with 1.0% Tween 80 and enzyme with protease activity as per USP | 900 | 5, 10, 15, 20, 30 and 45 | 2021-04-22 |
